Advances in the biological approach to cancer therapy are reviewed. The mechanisms of actions, clinical effects and uses of interferons, the first biological modifiers to be used, are reviewed first. The interleukins and monoclonal antibodies are also mentioned in detail. This review also covers the clinical use and production of Iymphokine activated killer cells, which are used in conjunction with interleukin-2. A brief review of tumour infiltrating lymphocytes, which comprise a subset of lymphocytes found within solid tumours is given. In mice, tumour infiltrating lymphocytes have been shown to be more therapeutic than Iymphokine activated killer cells. Tumour necrosis factor, a protein released by activated macrophages in response to stimulation by endotoxin, is also briefly mentioned although clinical data are disappointing. Finally, the role which oncogenes may play in cancer therapy and understanding is discussed.
INTRODUCTION
J ust as the pioneering of combination chemotherapy provided the great oncological advance of the 1960s and 1970s the biological approach to cancer therapy appears to be one of the major breakthroughs of the 1980s. Increasing frustration with the incurable nature of the vast majority ofsolid tumours, coupled with the commercial pressure on biotechnology companies to produce effective compounds, has resulted in a dramatic increase in the development of 'biologicals'. The exponential expansion in recombinant DNA technology has facilitated large quantities of highly purified biological substances for use in clinical trials. The history of successful therapeutics in oncology is replete with drugs, strategies and radiation regimens initially thought to cause toxic effects in excess of benefit. To date biological modifiers have been used in patients with widespreadmetastaticdisease in whom other therapies have failed. The tumours in which these compounds have been most successful are renal cell carcinoma and malignant melanoma, both of which are unusual in that they are relatively unresponsive to conventional treatment but, in a small proportion of patients, undergo spontaneous remission. An immunological basis for this unpredictable behaviour seems highly likely. The first biological modifiers to be used, about which the most is known, were the interferons. These illustrate the spectrum of diseases, effects and responses which are exemplified throughout the entire range of biological compounds. The interferons have been closely followed by the clinical evaluation of other lymphokines. INTERFERONS The interferons are secreted proteins with similarbiological properties, first described by Isaacs and Lindemann in 1957. 1 Their first known property was an ability to induce an antiviral state. More recently, they have been found to have potent immunomodulatory and antiproliferative actions. Interferons are classified according to their antigenic type and primary cell of origin, being produced by leucocytes (a), fibroblasts (~) and Tvlymphocytes (y). Type I (a and~) are produced in response to viral infection, and type II (y) in response to Tlymphocyte antigen stimulation or mitogens. ' Many studies suggest that interferons Table 1 Properties of a-,~and y-interferons playa major role in host defence, including increased natural killer cell activity, macrophage activation and increased expression of major histocompatibility complex (MHC) class I and II antigens, all of which are likely to facilitate the recognition and lysis of susceptible target cells. The extractionand purificationof the various types of interferon from cellular sources was hampered by the fact that interferons from different sources are not always of one type. Many of their actions are species specific; it has only been through gene cloning that the structural relationships of the interferons have been understood. Although polyclonal and monoclonal antibodies have been raised against specific interferons, there is often cross-reaction. Interferon cyclic DNA was first cloned in 1980. 3 Most of the work has been performed with a-interferon whose genes are closely linked and arranged in tandem on chromosome 9. 4 Human~-interferon has been cloned and two different species of the gene isolated ( Table 1) .
Mechanisms of action
The mechanisms of action are very complex and multiple sites are likely to be involved ( by the binding of cell surface receptors. (X-and~-Interferons are thought to occupy the same receptor site and y-interferon a separate one. Interferon is internalized and a rise in cyclic GMP follows with a subsequent rise in cyclic AMP. In association with these changes, the activity of several different enzymes may rise or fall.' The precise molecular cascade resulting in the physiological effects has not yet been determined.
Effects
The inhibitionof viral replicationis achieved by much lower doses than affect the immune system 6 In some systemsboth tumour necrosis factor (TNF) and interleukin-l (IL-l) can exhibit antiviral effects. Not only does this illustrate the overlap in functions and interplay between these molecules, but it begs the question as to whether they should all broadly be classified as interferons. It is believed that the antitumour action of (Xinterferon is not mediatedby the host immune system but by the direct inhibition of tumour cell growth or host -tumour cell interaction. One explanation of the efficacy of interferon in hairy-cell leukaemia is defective interferon production whereby exogenous n-interferon corrects an endogenous defect. Interferons have diverse effects on the immune system and act as communication molecules between cells involved in the immune response.' The timing of administration is important because the presence of interferons before antigen administration may reduce antibody production and the presence of interferons afterwards may enhance the same response. As yet relatively little is known about the interactions of interferons with other mediators, particularly in relation to malignant disease. s
Toxicity
It was initially thought that many of the side-effects apparently caused by interfer-Biological approaches to cancertherapy ons were due to impurities, but they still occurred following the injection of pure recombinant interferons." Malaise and fever appear to be non-specific, similar to those produced by endotoxins. They subside rapidly and can be prevented with aspirin and paracetamol. Changes occur in corticosteroids and circulating zinc levels which may influence the course of a patient's disease.'? At high doses there are profound effects on the nervous system whereby drowsiness and disorientation may occur. Dysfunction of the central nervous system may be the major dose-limiting factor for systemic interferon at high doses (100 -200 X 10 6 IU/m 2 ) . Abnormal liver function tests and altered serum calcium levels also occur, although they do not explain the cerebral changes. There appears to be no correlation between the severity of sideeffects and serum levels of interferon. Many of the unwanted side-effects are produced in healthy volunteers when injections of purified interferon result in serum levels comparable to those seen in influenza; it seems reasonable to postulatethat the mechanism by which they occur is the same. II
Interferons and oncogenes
There is evidence of the relevance of interferons to cell proliferation whereby they act as negative growth factors. The role of cellular proto-oncogenes in regulating the ability of cells to proliferate and the expression of transformed or malignant phenotypes has been used in this connection. The expression of c-myc in Daudi (Burkitt's lymphoma) cells has shown that the concentration of c-myc mRNA is diminished in Daudi cells within 24 h of exposure to human~-interferon. The effects are accompanied by inhibition of cell proliferation. It appears that the decrease in c-myc mRNA concentration is due to decreased processing or stability and not to any change in the rate of transcription. The decrease in concentration is also too rapid to be ex-plained by the accumulation of Daudi cells in the OJOI phase of the cycle. Further investigation has simply served to emphasize the multifactorial nature of cell growth regulation and malignant transformation, and it seems unlikely that changes in c-myc expression are the primary or sole cause of the inhibition of cellular growth by interferons."
Clinical trials
Although understanding of the mechanisms of action of interferons in malignancy has some way to go, many trials have been carried out in malignant disease with some degree of success. The first large scale clinical trial was begun in 1971 at the Karolinska Hospital, Stockholm. Relatively impure leucocyte interferon was used as adjuvant treatment in patients with operable osteogenic sarcoma. Post-amputation patients were treated daily with 3 x 10 6 IU, intramuscularly, for 1 month. Over the subsequent 18 months they received the same dose three times a week. Thirty-three patients were compared with a historical control group and the difference in outcome was marked, however, at the time of the study there was a change in assessment and treatment of the. disease, and the two groups were not truly comparable." Subsequent prospective trials failed to show any improvement in survival for the interferon-treated group over the control group.14 At Stanford University, patients with good prognosis histology non-Hodgkin's lymphoma were followed for 1 year with no other treatment. Response, measured by lymph node diameter, was assessed frequently during this time. Several dramatic regressions were seen, again using partially purified leucocyte interferon." Extensive data with recombinant interferon confirm these responses, but suggest that their duration is short."
Interferons may reduce the rate of immunoglobulin synthesis by normal and neo-194 plastic B lymphocytes and improvements have certainly been seen in myeloma patients after the administration of interferon.I? Recent data with recombinant preparations suggest a role for interferon in combination with alkylating agents."
Melanoma has shown consistent, reproducible responses to interferons. Only therapy using the conventional modalities has been disappointing and response rates in excess of 10 -15% are a bonus. Responses were first seen with natural human leucocyte interferon and this led to further work using other species of interferon. The experience with~and 'Y-interferons is more limited but, nevertheless, objective response rates of 10 -15% occur. Dose reduction reduces toxicity without affecting efficacy and interferons in conjunction with chemotherapeutic agents may further augment responses. 19 In 1978 the American Cancer Society initiated a multicentre trial in which 45 patients with malignant melanoma at UCLA, Memorial and Yale Universities received I, 3 or 9 IU/day, intramuscularly for 42 days. There was one partial response, two minimal responses and no complete response. Few responses have been seen with intralesional injection of interferon in the treatment of melanoma."
The most promising clinical results have been seen in the treatment of hairy-cell leukaemia.v-", Quesada et al. 22 reported the successful treatment of 10/11 patients using a-interferon. The results compared favourably with chemotherapy, without the toxicity. It is still too early to be sure whether survival is also improved.
In renal cell carcinoma, conventional therapy attains a 20% response rate. Many of the original immunological manipulations carried out were likely to induce the activity of interferon, but levels have not been measured.
At the Maryland Anderson Hospital using 3x10 6 IU/day for 30 days, five partial responses (26%) and two minor responses (partial plus minor 36%) occurred from a total of 19 patients. The median duration of response was just over 4 months and responders had lower nadir granulocyte counts thereby suggesting a greater biological effect of the interferon. Subsequently, the duration of treatment was increased with some studies showing a dose -response relationship." INTERLEUKINS IL-l is a macrophage derived cytokine that activates certain T lymphocytes. Subsequently, it stimulates IL-2 production which was originally described as aT-cell growth factor causing proliferation of activated cells made competent, by an initial activation process, to go through the G1 phase of the cell cycle." It was, subsequently, shown to cause T-cell activation for cytotoxicity and chemotaxis of certain subpopulations of cells, including T-cells bearing the CD4+ surface marker. IL-2 directly induces the release of other lymphokines and the physiological roles of these molecules are not yet fully understood. They are currently the subject of intensive investigation and the jigsaw is being put together piecemeal.25.26
Mechanisms ofaction
The actions of IL-2 involve both the production of several different lymphokines and the interaction of different component cells of the immune response. At best only a model for these is available. This currently involves the interaction of an antigen with an antigen-presenting cell, usually a monocyte or a macrophage. Subsequently, several factors are released including IL-l which, together with the antigen, stimulates several cells including CD4+ T-cells to release IL-2, the second signal in lymphocyte mitogenesis. IL-2 interacts with a receptor and causes both up-regulation of IL-2 receptors on T-cells and the release of other lymphokines including y-interferon Biological approaches to cancer therapy and tumour necrosis factor (TNF).
As experience of the 'biologicals' has accumulated, their use in various regimens and combinations has increased Immunotherapy can be passive, i.e. by infusion of the relevant lymphokine into the patient, or active, i.e. by induction of a particular lymphokine as a result of the presence of other biologicallyactive molecules (adoptive immunotherapy).
Arriving at the correct dose regimens, schedules and routes of administration in man would be time consuming, potentially dangerous and expensive. Much of this work has, consequently, been carried out in animals, particularly mice. Unfortunately, many of the soluble factors involved are species specific and so the validity of many of these experiments must be questioned. Work in mice carrying subcutaneous transplants of methylcholanthrene induced sarcomas was performed to compare the tumour inhibitory effect of highly purified recombinant IL-2 with that of unpurified human and rat lymphoid IL-2. The latter was significantly more effective, an indication that other lymphokines may participate in the antitumourefficacy oflocal IL-2. The work also demonstrated a correlation between tumour sensitivity to the effect of recombinant IL-2 in vivo and susceptibility to the cytolytic effects of recombinant IL-2-activated syngeneic killer spleen (LAK) cells in vitro. This is explained by LAK cells being the effector mechanism for the efficacy of local recombinant IL-2. It may be possible to extrapolate from this to use LAK cells in vitro as a predictor of sensitivity to local recombinant IL-2. Other routes of administration have been used in animal experiments. Intraperitoneal injection oflL-2, followed by intravenous LAK cell administration and concurrent intraperitoneal cyclophosphamide showed that this form of adoptive immunotherapy mediates regression of micrometastases in a particular organ, but is ineffective against intrad-ermal or gross metastatic tumour nodules. 27 Using animals Rosenberg et al. 28 ,29 have demonstrated that therapy with IL-2 alone or in combination with LAK cells can decrease the size of established pulmonary and hepatic metastases from experimental tumours. As a result of these studies, the use of IL-2 has been extended to patients with advanceddisseminatedcancer in whom conventional treatment has failed. IL-2 is the linchpin of much current work involving the 'biologicals'. There has been a plethora of studies, many of which have used other lymphokines in combination. Initially, IL-2 was used in high dosage, alone or with LAK cells, as a repeated bolus injection. Administered as an intravenous bolus it has a distribution half-life of? -10 min and a clearance half-life of 30 -60 min. Of 221 patients given this therapy, 16 had a complete regression of all known disease and 26 had a partial regression.
Toxicity
The use oflL-2 in high dose as a bolus was found to be very toxic; it affects the endothelium causing emigration of lymphoid cells from the peripheral blood and also produces a 'vascular leak syndrome' observed in rodents." This appears to occur in humans, as measured by albumin excretion."
Fluid retention is usually manifest as peripheral and pulmonary oedema, but myocardial infarctions and injury have also been recorded, first by Rosenberg's group and since then by other groups. Myocardial infarctions and injury are thought to be due to vascular leakage at the level of the heart muscle." The use oflL-2 in continuous infusion was better tolerated, although there is some debate as to whether the response rates are as good." Side-effects include fluid retention resulting in pulmonary, peripheral and cerebral oedema which itself produces confusion followed by con-196 vulsions. Fevers, nausea, vomiting, eosinophilia and anaemia are also commonly seen. In Rosenberg's original work, a high proportion of patients required admission to intensive care units. Subsequent trials have been possible on out-patients, but the results are not as encouraging as those seen at the National Cancer Institute." Further understanding of the mechanisms by which toxicity occurs is required in order to reduce it. Experimental work to ascertain the role of immunocompetentcells in haemopoiesis has thrown some light on the haematological side-effects oflL-2 and LAK cell therapy. A colony stimulating factor which gave rise to a high number of eosinophil colonies was detected and the presence of LAK cells led to a decrease in the number of burst forming units erythroid. These two findings may explain the eosinophilia and anaemia observed in patients receiving this therapy."
Dose
Defining the dose regimen of IL-2 has largely entailed a process of trial and error, balancing the side-effects against an adequate dose to produce a response. One study examined the effects of low dose recombinant IL-2 preceded by low dose cyclophosphamide in the treatment of malignant melanoma. Six of 24 patients who received more than one 2-week cycle had a response (one complete response and five partial responses). Mean response duration was 5 months. The significant findings are that all six responders were found to have LAK cell activation and only 2/24 patients required hospitalization, since toxicity was so moderate." The use of IL-2 combined with TNF in their usual dose regimens would be both highly toxic and expensive. A study to look at the synergy of these two lymphokines in recombinant form, in mice, was carried out at low doses. Used alone they produced no useful effect but, when combined, there were signifi-cant antitumour effects in mice with methylcholanthrene induced sarcomas. This effect was dependent on the inherent immunity of the mice and did not occur in immunosuppressed mice. The sequence of administration is again important, the prior administration of IL-2 produced more significant regression than when TNF was given first."
Effects on other lymphokines
In patients with malignant ascites the effects of intraperitoneal IL-2 on tumour associated lymphocytes (TALs) and peripheral blood lymphocytes were examined. The TALs showed an important increase in the proportion of cells expressing IL-2 receptors of LAK antigen, and sharp increases in natural killer cell activity and the generation of LAK activity de novo were also observed." LYMPHOKINE ACTIVATED KILLER CELLS LAK cells have been used in conjunction with IL-2 and results to date suggest that responserates are improved over IL-2 alone. This is certainly true of Rosenberg's patients with renal cell carcinoma and has led to a randomized trial being undertaken to resolve the question. It may be that LAK cells are essential to the best response rate but, as yet, the physiological pathway responsible for their regulation in the normal cell, or which other lymphokines are involved in their activation are not understood.
Clinical use
The adoptive transfer of activated lymphocytes into cancer patients is a complicated procedure which is not yet possible on a large scale. Lymphocytes are harvested from patients by leukaphoresis and incubated with recombinant IL-2 so that they become LAK cells. These are then infused back, intravenously, into the patient together with recombinant IL-2. Of 25 can-Biological approaches to cancer therapy cer patients treated in this way; there were 11 responses one of which was complete. Responses were seen in patients with melanoma, renal cell carcinoma and colorectal tumours. The toxicities attributable to IL-2 were dose-limiting." Where autologous and allogeneic LAK cells have been used alone they appear to be effective in a proportion of patients and are without immune side-effects."
Production
Until recently the production of LAK cells as described above has only been possible on a relatively small scale. Long-term culture of cells in recombinant IL-2 containing medium, however, increases LAK activity on a per cell basis with an average 20 -lOO-fold expansion over 14 -21 days. Stimulation of peripheral blood lymphocytes with anti-CD3 antibody results in a 300 -lOOO-fold increase in cell number without any loss of LAK activity. Such cells can be further stimulated with other lymphokines to enhance LAK activity with the possibility of large scale 'production' for experimental and therapeuticpurposes." TUMOUR INFILTRA TING LYMPHOCYTES Experiments in mice have identified tumour infiltrating lymphocytes (TILs) as tumoricidal cells that are more therapeutic in vivo than LAK cells and less dependent on adjunctive systemically administered IL-2 to mediate the antitumour effects. Consequently, they are of greater use in clinical trials. TILs comprise a subset of lymphocytes found within solid tumours which can be selectively expanded from tumour digests cultured in the presence of IL-2.
Mechanism
The expression of MHC antigens of tumour cells and a subpopulation of TILs were examined in 14 glioma and 13 metastatic brain tumour tissues. In both cases most of the TILs were T-lymphocytes and both phenotypesof the cytotoxicand helper/ inducer T-lymphocyte were found. Examining the MHC antigens revealed~2-mi croglobulin located intensely on tumour cells in all cases. HLA-DR (the monomorphic determinant of the human leucocyte antigen) was shown in 10 glioma and five metastatic tumours. Again a correlation was seen between the number of TILs and MHC antigen expression on tumour cells.42 A pilot study was carried out to look at the practicability of administering IL-2 expanded TILs to humans with metastatic cancer. Twelve patients (six with melanoma, four renal cell, one breast and one colonic cancer) were treated with varying doses and combinations of: TIL, 8 x 10-9 -2.3 X 10-11 cells/patient; IL-2, 10 000 -100 000 IU/kg three times daily to doselimiting toxicity; and cyclophosphamide, up to 50 mg/kg. Two partial responses were seen, with pulmonary and mediastinal masses regressing in one patient and a lymph node mass in the other (melanoma and renal cell carcinoma, respectively). Toxicities were comparable to those seen with IL-2, none being directly attributable to TILs. In five of the six melanoma patients TILs demonstrated lytic activity specific for the autologous tumour targets in short-term chromium release assays, unlike the non-specific activity seen with LAK cells. It would appear that a lymphocyte subset with enhanced tumoricidal capacity has been identified and that further work is needed to elucidate its appropriate administration schedule."
In experimentalwork involvingpatients, sequential tumour biopsies were obtained before, during and after treatment with IL-2, with or without the adoptive transfer of LAK cells. Infiltrating lymphoid and tumour cells were characterized in frozen sections using monoclonal antibodies and the avidin -biotin complex immunoperoxidase technique. In five patients there 198 was objective tumour regression (one complete response in a follicular lymphoma and four partial responses in melanoma). Four patients were non-responsive. Responsiveness showed a pronounced infiltration with T-cells after treatment, whereas in non-responders there was no significant increase in lymphoid cells after therapy. No difference was noted between groups before therapy. In four out of five responders tumours were positive for HLA-DR before therapy and, in the remaining responder, the tumour became positive during treatment. Non-responders had HLA-DR negative tumour cells before and after treatment. It appears that the expression of HLA-DR in tumour cells may play a role in the response to IL-2 with or without LAK cells and that marked infiltration by Tcells accompanies and, possibly, mediates such a response." TUMOUR NECROSIS FACTOR TNF is a protein released by activated macrophages in response to stimulation by endotoxin. In vivo it characteristically produces necrosis of tumours, but is also found to kill tumour cells in vitro, inhibit lipoprotein lipase, stimulate granulocytes and fibroblasts, damage endothelial cells and possess antiviral activity.
The production of recombinant TNF has been possible since 1984, when it was first cloned." Its role both physiologically and in cancer is still uncertain, although it has a definite role in the production of endotoxic shock.
A study carried out to determine its maximum tolerated dose, pharmacokinetics and anticancer effect on 18 patients with advanced cancer was performed at the Royal Marsden Hospital, London. Doses starting from 1.2 x 10-6 IU/m 2 and increasing to 9 x 10-3 IU/m 2 were used. Patients were very carefully monitored and TNF levels measured by enzyme-linked immunoadsorbent assay (ELISA). One-third of patients experienced febrile symptoms, which may result in rigors and were not related to dose in incidence or severity. Hypotension was dose-related, appearing in three of seven patients receiving a dose of over 9 x 10-5 IU/m 2 • Abnormal levels of liver enzymes were transient but doserelated, as was a neutrophil leucocytosis.
Objective disease response was seen in only three patients, all of whom were partial responders with lymphomas. No evidence of elevated endogenous TNF was found in patients with malignant disease." Clinical data from many centres using recombinant TNF alone has been very disappointing, with few documented tumourregressions. There is almost certainly little place for TNF when used as a single agent.
MONOCLONAL ANTIBODIES
Since the development of monoclonal antibodies by Kohler and Milstein in 1975,47 their use in the diagnosis, investigation and treatment of cancer has become increasingly specific and efficient. They were originally produced after hybridization between a malignant myeloma cell line in continuous culture and spleen cells from a mouse immunized against a specific antigen. It is now possible to produce inexpen-sively an infinite range of these antibodies in relatively large quantities. This development was followed by the discovery of tumour associated antigens by producing large numbers of antibodies against tumour cells and then screening each antibody for its reactivity with a range of tissues. This antibody is then selected and produced in bulk with knowledge limited to the tissue distribution of the target antigen. As yet no highly specific tumour antigens exist, the degree of specificity is only relative ( Table 2) .
Diagnosis
In diagnosis many of the important breakthroughs have been in the area of histopathology. Antibodies to intracellular components such as the intermediate filament proteins and to extracellular matrix components found in the vicinity of the tumour are being used to distinguish different tumour types. The cytokeratins form the intermediate filaments of epithelial cells and are found only in epithelial and mesothelial cells. As such they can be effective diagnostic tools in discriminating between carcinomas and lymphomas, and for identifying target cells within the tissues. Although the search for a specific tumour marker has been disappointing, panels of antibodies can be used to separate morphologically indistinct tumours. Equally, the site of origin can be determined from small biopsy specimens, aspirates and micrometastases. Lymphoma phenotyping has been the most successful area in which phenotyping can be used to distinguish grade and cell type."
To obtain accurate stageing in breast cancer it is important to identify both the presence and extent of metastatic deposits. The detection of micrometastases in histological sections, with the use of monoclonal antibodies, may be more sensitive than any other methods yet available. The expression of the tumour associated epithelial antibodies (those directed to human milk fat globule), may be modulated by the environment, unlike the expression of the cytokeratins but, as yet, they are the most reliable breast tumour marker which has been found. Antigens expressed at the cell surface may be of use in the antibody localization of a tumour. Melanomas were among the first neoplasms investigated using monoclonal antibodies, several antigens have been defined which are preferentially expressed in melanoma. Where other factors are highly suggestive, the presence of Sloo positivity (an acidic protein widely found in cells of neural crest origin) can help to clinch the diagnosis. Although the expression of some melanoma antigens is 20 -lOoo-fold greater in melanomas than in normal tissues, there are no absolute qualitative differences. Three major antigens are detectable in virtually all primary melanomas tested, with varying frequency. This heterogeneity suggests that a combination of antibodies would be advantageous for most clinical purposes."
Imaging
Monoclonal antibodies coupled to a suitable radiolabel have been used for tumour imaging. Monoclonal anticarcinoembryonic antigen (CEA) antibody has been used 200 with results that suggest a sensitive technique using emission computerized tomography scans which compete with the other radiological diagnostic tests such as computerized tomography and magnetic resonance imaging. 123I-Labelled small fragments of monoclonal antibody with high affinity for CEA represent a definite improvement over previously published results. Using intact polyclonal CEA, Begent et al. 50 reported an increase in the definition of tumour images by removing circulating radiolabelled antibodies using liposome entrapped second antibodies. Among the different tracers proposed for carcinoma of the colon diagnosis with immunoscintigraphy, Begent et al." used the antigen binding fragment of the monoclonal antibody labelled with 1231. Although this has a short physical half-life the definition of tumour images obtained at 24 his superior to that obtained with whole antibody.
Treatment
It is now possible to produce 'humanized' antibodies, use antibody fragments and the degree of specificity of antibodies to tumour cells has continued to be enhanced. Early work was carried out in leukaemias and lymphomas where there is a source of readily dispersed cells and their products to which monoclonal antibodies can be raised. The initial problem preventing further successful treatment was the production of antimouse immunoglobulin. It is now possible for the antigen binding site of a mouse antibody to be cut out and grafted onto a human immunoglobulin molecule so that it is recognized as human by the immune system." Such antibodies have now undergone clinical trials in patients with recurrent non-Hodgkin's lymphoma. 52 Other problems included inaccessibility (e.g. brain and testis) and the development of resistant mutants by various mechanisms (altered antigenic determinants and sparse or no surface antigen). These problems can be. overcome by swamping the tumour with antibody or reducing the bulk of tumour with some other agent beforehand. Chronic antigen modulation can also be avoided by allowing a reasonable period between treatments.
An ideal target for antibody therapy would be entirely specific for tumour cells, associated with their neoplastic behaviour and easily accessible. In the treatment of melanoma, antibodies may be cytotoxic or cytostatic and may enable melanoma cells to be killed by activating human complement or antibody-dependent cellular cytoxicity. Large doses of antibody can be repeatedly given over a 10-day period without unacceptable toxicity, and administering 150 mg or more over a 10-day period results in melanoma cells in tumour biopsies being shown to bind antibodies where there was no significant binding to normal stromal cells.
Radioimmunotherapy is less well developed than radioimmunodetection, but encouraging results have been seen in some malignancies. The antibodies used exploit the quantitative differences in antigen expression between the tumour and the adjacent normal tissues. An ideal malignancy for the pioneering use of this treatment is carcinoma of the ovary which is usually confined to the peritoneal cavity and, with the aid of surgery and chemotherapy, is often of small bulk. Twenty-nine patients with resistant ovarian cancer were treated with intraperitoneal 13 II-labelled monoclonal antibodies. Two responses were seen in 15 patients with disease of~2 cm in diameter. Of six patients with microscopic disease, four were disease free at follow-up at a median duration of 17.5 months. Eight patients with gross disease showed no significant response."
Radiolabelled antigen binding fragments specific for melanoma antigens can localize in melanoma tissue when injected in-Biological approaches to cancertherapy travenously into patients. Data on the localization of 131I-labelled anti-p97 antigen binding fragments suggest that these can be used to deliver a therapeutic dose of radioactivity to the tumour without causing unacceptable damage to. normal tissues. Imaging techniques can be used to determine how much of the therapeutic agent is taken up in the tumour before a patient is treated so that uptake can be related to the therapeutic dose necessary. Unfortunately, even the most specific antibodies so far tested localize only 5 -10 times better in tumours than in normal tissues; hence, there is considerable variation and the consequent short-and long-term damage to bone marrow, intestine, etc., which this carries with it.
Recent work using monoclonal antibodies conjugated to a pro-drug is a theoretically useful technique where specific treatment of microscopic disease is appropriate without the side-effects of current alternatives (such as the treatment of sanctuary sites or cerebrospinal fluid). So far this treatment has been used with promising results on human tumour xenografts in nude mice."
Toxicity
Treatment with monoclonalantibodiesalone has remarkably few adverse reaction, in spite of the large quantities used. Fever, thought to be due to endogenous pyrogen, is the most common side-effect. Occasionally bronchospasm, urticaria, anaphylaxis and impaired creatinine clearance have been seen.
The major limitation which faces monoclonal antibody therapy is that conjugates with radionuclides, toxins and chemotherapeutic agents are still not able to gain access to the centre of bulky tumour masses. Until this is possible with acceptable toxicity to normal tissues monoclonal antibodies are useful only as an adjunct to existing therapeutic modalities.
ONCOGENES
No discussion on advances in cancer would be complete without reference to the progress made in molecular biology in the past decade. The discovery of viral oncogenes with counterparts in normal mammalian cells have considerable diagnostic and therapeutic potential. Oncogenes are defined as those sequences of DNA whose altered expression or abnormal product is pivotal to the production or maintenance of the malignant state. Their function appears to be closely related to the control of gene expression and cellular proliferation. The widespread existence of genetic abnormalities in malignant cells (e.g. Philadelphia chromosome in chronic myeloid leukaemia) along with the high incidence of malignancies in certain inherited disorders are only part of the evidence pointing to a genetic basis for malignancy. Cellular oncogenes may be found at the cell surface, in the nucleus or cytoplasm, as GTP-binding proteins, enzymes and growth factors involved in the alteration of proteins concerned with cell replication. It is believed that their alteration is related to the development of malignant phenotype. By deciphering their function in normal cells it is hoped that their role in the control of cellular differentiation and proliferation can be established. Although clinical application is currently limited, oncogene expression has been examined in a wide range of primary tumours and metastases. Released oncogene products may be useful tumour markers for immunocytochemistry purposes and, when linked to radionuclides, they have enabled accurate tumour localization. 55 In some instances oncogenes have proved a useful tool in predicting the tumour biology and natural history of a particular patient's disease. There is an important association between prognosis and epidermal growth factor receptor (c-erb-B I) status. This is an 202 important predictor of relapse-free and overall survival in breast cancer. 56 This discovery of oncogenes has clearly given tremendous impetus to the understanding of the biology of cancer. It also provides new targets for developing pharmacological agents. Growth factors, growth factor antagonists and antibodies to the receptors for growth factors are clearly fruitful areas for new drug design. Furthermore, nucleoside analogues of GTP may successfully inhibit the ras protein even though its function is as yet undefined. Many oncogene products, such as tyrosine kinases, exert their effects by phosphorylating tyrosine and other amino acids. Several agents are available which can block this activity. The most intriguing are suicide peptides containing tyrosine. These molecules mimic the kinases' natural substrate and bind with high affinity to the enzyme, thereby irreversibly destroying it. Such peptides are arousing intense interest in the drug industry, but as yet have not entered clinical trials. CONCLUSION The potential permutations and applications of biological therapy for cancer are legion. Perhaps the most important aspect is an increased understanding of the molecular mechanisms of malignancy through which biological manipulation can be tailored to an individual "tumour. Although studies have not demonstrated high responses they are comparable with the advance seen with chemotherapy in its early days and, although the evolution of treatment is apparently slower, there are definite improvements in the right direction. As yet only relatively small numbers of patients have had access to, or have been suitable for, such treatment. With further refinements in production, administration and an increase in the specificity of treatment the possibility of curing mestastatic solid tumours may become a reality.
